Waycross Partners LLC Raises Holdings in Becton, Dickinson and Company $BDX

Waycross Partners LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,966 shares of the medical instruments supplier’s stock after acquiring an additional 3,632 shares during the quarter. Becton, Dickinson and Company comprises approximately 1.8% of Waycross Partners LLC’s investment portfolio, making the stock its 26th largest holding. Waycross Partners LLC’s holdings in Becton, Dickinson and Company were worth $18,391,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Steph & Co. raised its holdings in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $29,000. Finally, Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,188 shares of company stock valued at $765,120. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $158.14 on Monday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market cap of $43.57 billion, a PE ratio of 40.04, a price-to-earnings-growth ratio of 11.19 and a beta of 0.21. The business has a 50-day simple moving average of $148.99 and a 200-day simple moving average of $166.18.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Analyst Ratings Changes

A number of brokerages recently issued reports on BDX. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler dropped their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Barclays increased their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, The Goldman Sachs Group dropped their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $180.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.